New research and clinical criteria for Alzheimer\'s disease (AD) have recently been proposed, which include biomarker information on Alzheimer\'s plaque and tangle pathology, or AD-typical structural brain changes, as supporting or essential elements of an AD diagnosis.^[@bib1],\ [@bib2],\ [@bib3]^ In a large group of patients with both genetic and cerebrospinal fluid (CSF) biomarker data, we here show that biomarker-assisted diagnosis-making almost doubles the effect size of the association between the ɛ4 variant of the apolipoprotein E (*APOE*) gene and AD.

We included clinically diagnosed patients with either AD dementia (*n*=309) or mild cognitive impairment (MCI) due to AD (*n*=287), cognitively normal controls (*n*=251) and patients with MCI who remained stable over at least 2 years (*n*=399) or developed dementias other than AD (*n*=99) (Table 1, [Supplementary Material](#sup1){ref-type="supplementary-material"}). All had *APOE* ɛ2/ɛ3/ɛ4 genotypes and results on the CSF biomarkers total tau (T-tau), phosphorylated tau (*P*-tau) and the 42-amino-acid isoform of amyloid-β (Aβ42) determined. These CSF biomarkers reflect the core elements of Alzheimer\'s pathology^[@bib4]^ and are strongly associated with AD in cross-sectional as well as longitudinal follow-up studies ([Supplementary Material](#sup1){ref-type="supplementary-material"}).^[@bib5],\ [@bib6]^

AD dementia and MCI-AD patients were first pooled into one clinical AD group (*n*=596) and compared with all remaining categories that were designated non-AD (*n*=749). A positive *APOE* ɛ4 carrier status (one or two ɛ4 alleles) was overrepresented in the AD group and yielded an odds ratio (OR) of 4.45 (95% confidence interval (CI) 3.52--5.62) for a clinical diagnosis of AD at inclusion or follow-up ([Figure 1](#fig1){ref-type="fig"}). This OR is similar to the AlzGene meta-analysis of *APOE* (3.68, 95% CI 3.30--4.11, [www.alzgene.org/meta.asp?geneID=83](http://www.alzgene.org/meta.asp?geneID=83), November 2012 freeze). Similarly, we tested the association of *APOE* ɛ4 with AD, comparing the 596 AD patients with the 251 cognitively normal controls, which resulted in an OR of 6.35 (95% CI 4.59--8.80).

Disregarding the clinical diagnoses and subgrouping all subjects into amyloid-positive, defined as CSF Aβ42 \<546 ng l^−1^ (*n*=779), and amyloid-negative, defined as CSF Aβ42 ⩾546 ng l^−1^ (*n*=563) (see [Supplementary Material](#sup1){ref-type="supplementary-material"} for details on cut-point determination), gave an OR for *APOE* ɛ4 as high as 6.27 (95% CI 4.93--7.98). Dichotomizing the material according to CSF T-tau or *P*-tau did not change the ORs as compared with clinical diagnosis only ([Figure 1](#fig1){ref-type="fig"}). Even though the OR for the ratio *P*-tau/Aβ42 (6.50 (95% CI 5.07--8.35)) was slightly higher than for Aβ42 alone, the difference was not statistically significant.

We also compared patients, again disregarding the clinical diagnoses, who had a complete CSF biomarker signature indicative of AD, that is, low Aβ42 and both high T-tau and *P*-tau (*n*=438, see [Supplementary Material](#sup1){ref-type="supplementary-material"} for a detailed description of the signature), with subjects with a negative CSF biomarker pattern (*n*=414). The biomarker diagnosis strengthened the association to *APOE* ɛ4; the OR increased from 4.45 (95% CI 3.52--5.62) in pure clinical diagnosis to 7.66 (95% CI 5.65--10.39) in patients classified on the basis of biomarker data alone.

Finally, ORs were calculated on subjects having both a clinical diagnosis and a concordant complete biomarker profile (n(AD)=324; n(control)=155). This approach resulted in an even stronger association of *APOE* ɛ4 with AD (OR 10.4, 95% CI 6.65--16.3). Similar effects were seen when comparing non-carriers with ɛ4 heterozygotes and homozygotes across the different diagnostic groups ([Figure 1](#fig1){ref-type="fig"}, [Supplementary Material](#sup1){ref-type="supplementary-material"}).

These results have several important implications. First, *APOE* ɛ4 appears as strongly associated with amyloid pathology as clinical AD. Second, clinical criteria that incorporate biomarker information on Alzheimer\'s pathology give a stronger association with *APOE* ɛ4 than clinical diagnosis alone. This is compatible with the presumed higher diagnostic accuracy of the revised clinical approach,^[@bib1],\ [@bib2],\ [@bib3]^ and has also been seen in a series of neuropathologically verified AD cases and controls.^[@bib7]^ Third, the approach of combining clinical with biomarker data may increase the power of genetic association studies, as well as the potential to provide insights into the mechanistic pathways through which genetic risk factors may exert their effects.
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